GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED
This entity operates as an intellectual property management and business support subsidiary for the LSE-listed British pharmaceutical and biotechnology multinational, GSK plc.
Get an alert when GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£16bn
+9.2% highest in 3 filed years
Employees
—
Average over period
Profit before tax
£1.8bn
-14% vs 2024
Net assets
3-year trend · vs Industrials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £1,188,464,000 | £1,271,725,000 | £1,374,293,000 | +8.1% | |
| Operating profit | £1,005,657,000 | £1,421,058,000 | £1,183,306,000 | -16.7% | |
| Profit before tax | £1,568,495,000 | £2,110,106,000 | £1,813,672,000 | -14% | |
| Net profit | £1,327,008,000 | £1,843,399,000 | £1,352,401,000 | -26.6% | |
| Cash | — | — | — | — | |
| Total assets less current liabilities | £12,812,679,000 | £14,656,078,000 | £16,008,479,000 | +9.2% | |
| Net assets | £12,812,679,000 | £14,656,078,000 | £16,008,479,000 | +9.2% | |
| Equity | £12,812,679,000 | £14,656,078,000 | £16,008,479,000 | +9.2% | |
| Average employees | — | — | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | £0 | £0 | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 84.6% | 111.7% | 86.1% | |
| Net margin | 111.7% | 145.0% | 98.4% | |
| Return on capital employed | 7.8% | 9.7% | 7.4% | |
| Gearing (liabilities / total assets) | 2.7% | 2.2% | 2.4% | |
| Current ratio | 0.16x | 1.00x | 1.29x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors have taken into account that, as part of the Group, the Company has the support from the Group through the access to the Group cash pooling mechanism and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.”
Group structure
- GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED · parent
- GlaxoSmithKline Intellectual Property Development Limited 100%
Significant events
- “The one remaining state court case was voluntarily dismissed by the plaintiff in July 2025. Three of the four proposed class actions in Canada have been discontinued. The last remaining class action is not currently active, and is also expected to be discontinued.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Secretary | 2019-01-15 | — | — |
| BARCELO IGLESIAS, Cristina | Director | 2024-09-23 | Oct 1977 | British |
| FENT, Anna Mary Harcourt | Director | 2025-07-10 | Nov 1978 | British |
| GURUNLU RUSS, Demet | Director | 2024-06-25 | Oct 1971 | Turkish |
| RIVERS, Graham Paul | Director | 2023-07-18 | May 1971 | British |
| WALKER, Adam | Director | 2013-07-23 | Nov 1967 | British |
| EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Director | 2011-08-12 | — | — |
| THE WELLCOME FOUNDATION LIMITED | Corporate Director | 2011-08-12 | — | — |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| WHYTE, Victoria Anne | Secretary | 2011-08-12 | 2019-01-15 |
| ANDERSON, Jill Dawn | Director | 2023-03-01 | 2024-06-25 |
| ANDRIES, Jerome Charles Maurice | Director | 2017-10-01 | 2023-03-01 |
| BLACKBURN, Paul Frederick | Director | 2011-08-12 | 2016-02-01 |
| DINGEMANS, Simon Paul | Director | 2014-05-13 | 2019-05-01 |
| LA CORTE, Luigi Felice | Director | 2015-04-20 | 2017-09-30 |
| MACFARLANE, Fraser Gemmell | Director | 2013-07-23 | 2016-11-01 |
| PRIESTMAN, Kate Sophie | Director | 2016-12-09 | 2022-10-28 |
| REINAUD, Gregory Maxime | Director | 2024-01-30 | 2024-07-24 |
| REYNOLDS, Jemma-Louise | Director | 2024-04-04 | 2025-06-27 |
| SHAMSI, Ziba, Dr | Director | 2022-10-28 | 2023-09-13 |
| WHEATCROFT, James Russell | Director | 2019-07-01 | 2023-07-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Glaxosmithkline Intellectual Property Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 74 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-08-20 | AA | accounts | Accounts with accounts type full | |
| 2026-04-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-08-15 | AA | accounts | Accounts with accounts type full | |
| 2025-07-30 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-15 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-09 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-27 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-20 | CH01 | officers | Change person director company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-11 | CH02 | officers | Change corporate director company with change date | |
| 2024-08-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-14 | AA | accounts | Accounts with accounts type full | |
| 2024-07-31 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-18 | AD02 | address | Change sail address company with old address new address | |
| 2024-07-11 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-05 | TM01 | officers | Termination director company with name termination date | |
| 2024-04-15 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.